Oral News and Research

RSS

Norgine, Tranzyme commence dosing in ulimorelin Phase 3 study for restoring GI function after surgery

Tranzyme Pharma and Norgine B.V., have initiated dosing of ulimorelin in the first of two, Phase 3 pivotal studies - ULISES. Ulimorelin is Tranzyme's intravenous promotility agent in development for the management of postoperative ileus in hospital and acute care settings.

23 Feb 2011

USPTO issues patent to Synergy's SP-333 for treatment of IBD

Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that on February 1, 2011 the U.S. Patent and Trademark Office issued U.S. Patent No. 7,879,802, covering Synergy's novel drug candidate SP-333 to treat inflammatory bowel disease.

23 Feb 2011

Cannabis Science extract treatments help kill cancer cells

Cannabis Science, Inc. a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana derivative) products, is pleased to announce that numerous patients are reporting that Cannabis Science extract treatments are killing cancer cells.

23 Feb 2011

Amgen announces publication of XGEVA Phase 3 study results against solid tumors in Journal of Clinical Oncology

Amgen today announced the publication of results from a pivotal Phase 3 study of 1,776 advanced cancer patients with different types of solid tumors or multiple myeloma, which compared XGEVA to Zometa in preventing skeletal-related events.

23 Feb 2011

New study: Cannabis ingredient can improve appetites and sense of taste in cancer patients

The active ingredient in cannabis can improve the appetites and sense of taste in cancer patients, according to a new study published online in the cancer journal, Annals of Oncology today.

23 Feb 2011

Japan MHLW approves Sosei's NorLevo emergency contraceptive pill

Sosei Group Corporation, the biopharmaceutical company, today announced that Sosei Co., Ltd., its wholly owned Japanese subsidiary, was granted approval for its emergency contraceptive pill, NorLevo(R) TABLETS 0.75mg, by the Japan Ministry of Health, Labour and Welfare (MHLW). NorLevo(R) has thus become the fist emergency contraceptive pill available in Japan.

23 Feb 2011

Positive results from Harbor BioSciences' Triolex initial preclinical study for treatment of PD

Harbor BioSciences, Inc., which is investigating the use the company's proprietary compound Triolex as a treatment for Parkinson's disease with funding from The Michael J. Fox Foundation, announced positive results in initial preclinical studies.

23 Feb 2011

Infinity commences IPI-926 Phase 2 trial in patients with pancreatic cancer

Infinity Pharmaceuticals, Inc. today announced the initiation of the randomized Phase 2 portion of the trial of IPI-926 in combination with gemcitabine in patients with previously untreated, metastatic, pancreatic cancer.

22 Feb 2011

FDA approves OraSure's rapid antibody test to detect HCV

OraSure Technologies, Inc. announced today that its OraQuick HCV Rapid Antibody Test has now been approved by the U.S. Food and Drug Administration for use in detecting HCV antibodies with a fingerstick whole blood sample.

22 Feb 2011

ESMO creates new Community Oncology Working Group to ensure best standards of care

Receiving a cancer diagnosis is a devastating experience. Still under the shock of the bad news, patients must make many choices including who to turn to for advice and treatment, with the possibility to choose among a comprehensive cancer center, a university hospital or a community oncology hospital.

21 Feb 2011

Oral sex linked to cancer

Researchers from the United States have said that there is strong evidence linking oral sex to cancer. They have urged more study of how human papillomaviruses may be to blame for a rise in oral cancer among white men.

20 Feb 2011

Bangladesh cholera vaccine trial

Bangladesh will conduct the world’s largest clinical trial of an affordable cholera vaccine which could save tens of thousands of lives. The study began Thursday and involves nearly 250,000 people near the capital, Dhaka.

20 Feb 2011

Protalix: New data from taliglucerase alfa, oral GCD trials to be presented at Lysosomal Disease Network Symposium

Protalix BioTherapeutics, Inc., announced today that new clinical data from the switchover trial of taliglucerase alfa in Gaucher disease patients and preclinical data on oral enzyme glucocerebrosidase (oral GCD) will be presented today at the 7th Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2011 in Las Vegas, Nevada.

19 Feb 2011

Genzyme reports 3-year follow-up data from eliglustat tartrate Phase 2 trial for Gaucher disease

Genzyme Corporation today announced three-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate. Sustained or further improvements were observed across all endpoints, including bone disease, at the three-year timepoint.

19 Feb 2011

Platelet-rich fibrin matrix doesn't improve healing after rotator cuff repair

For years, doctors have used platelet rich plasma (PRP) to promote healing in various surgeries, but a recent study demonstrates that a type of PRP did not improve healing after rotator cuff repair.

18 Feb 2011

Tibotec begins enrollment in TMC435 phase 3 trial for treatment of HCV

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, announced today that the global phase 3 studies with TMC435 in treatment-naive patients and patients who have relapsed after prior SOC treatment have started.

18 Feb 2011

Rotary club plans variety of awareness and fundraising activities to eradicate polio

What do Italy's Trevi Fountain, India's Charminar monument, and the New York Stock Exchange building have in common? Each of these iconic landmarks will provide a dramatic backdrop for an equally dramatic message: End Polio Now. Those three words – representing Rotary's pledge to rid the world of this crippling childhood disease -- will be projected onto each structure during the week surrounding Feb. 23, the humanitarian service organization's 106th anniversary.

18 Feb 2011

Certain uses of terbutaline could lead to maternal heart problems and death, FDA warns

The U.S. Food and Drug Administration is warning that terbutaline administered by injection or through an infusion pump should not be used in pregnant women for prevention or prolonged (beyond 48-72 hours) treatment of preterm labor due to the potential for serious maternal heart problems and death. In addition, oral terbutaline tablets should not be used for prevention or treatment of preterm labor.

18 Feb 2011

Conatus commences multi-center CTS-1027 Phase 2b trial for HCV treatment

Conatus Pharmaceuticals Inc. announced today the treatment of the first patient in a multi-center Phase 2b clinical trial evaluating CTS-1027 in combination with Peginterferon Alfa-2a and ribavirin in a treatment experienced, hepatitis C null responder patient population. Safety, tolerability, and antiviral activity of the triple combination will be assessed after up to 48 weeks of therapy.

18 Feb 2011

Statin drug may help prevent blindness in diabetics

New University of Georgia research has found that a statin drug that is often known by the brand-name Lipitor may help prevent blindness in people with diabetes.

17 Feb 2011

Oral News and Research

Norgine, Tranzyme commence dosing in ulimorelin Phase 3 study for restoring GI function after surgery

USPTO issues patent to Synergy's SP-333 for treatment of IBD

Cannabis Science extract treatments help kill cancer cells

Amgen announces publication of XGEVA Phase 3 study results against solid tumors in Journal of Clinical Oncology

New study: Cannabis ingredient can improve appetites and sense of taste in cancer patients

Japan MHLW approves Sosei's NorLevo emergency contraceptive pill

Positive results from Harbor BioSciences' Triolex initial preclinical study for treatment of PD

Infinity commences IPI-926 Phase 2 trial in patients with pancreatic cancer

FDA approves OraSure's rapid antibody test to detect HCV

ESMO creates new Community Oncology Working Group to ensure best standards of care

Oral sex linked to cancer

Bangladesh cholera vaccine trial

Protalix: New data from taliglucerase alfa, oral GCD trials to be presented at Lysosomal Disease Network Symposium

Genzyme reports 3-year follow-up data from eliglustat tartrate Phase 2 trial for Gaucher disease

Platelet-rich fibrin matrix doesn't improve healing after rotator cuff repair

Tibotec begins enrollment in TMC435 phase 3 trial for treatment of HCV

Rotary club plans variety of awareness and fundraising activities to eradicate polio

Certain uses of terbutaline could lead to maternal heart problems and death, FDA warns

Conatus commences multi-center CTS-1027 Phase 2b trial for HCV treatment

Statin drug may help prevent blindness in diabetics

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News